Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11639927B2 · kind B2 · utility
4Cited by
117References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2020 |
| Grant date | May 2, 2023 |
| Priority date | — |
| Expiry date | Mar 14, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.